Close

Form 6-K InflaRx N.V. For: Sep 29

September 29, 2022 8:01 AM EDT

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


FORM 6-K


REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13A-16 OR 15D-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2022

Commission File Number: 001-38283


InflaRx N.V.
(Translation of registrant's name into English)


Winzerlaer Str. 2
07745 Jena, Germany
(Address of principal executive office)



Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐



INFLARX N.V.

On September 29, 2022, InflaRx N.V. issued a press release titled “InflaRx Submits Request for Emergency Use Authorization to US FDA for Vilobelimab for Treatment of Critically Ill COVID-19 Patients.” A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
 
2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 
INFLARX N.V.
   
Date: September 29, 2022
By:
/s/ Niels Riedemann
 
 
Name:
Niels Riedemann
 
 
Title:
Chief Executive Officer
 
 
3

EXHIBIT INDEX

Exhibit No.
 
Description
 
Press Release, dated September 29, 2022


4

ATTACHMENTS / EXHIBITS

EXHIBIT 99.1



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

SEC Filings